AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vanda Pharmaceuticals Q2 revenue up 27% to $29.3 mln, Bysanti NDA accepted for filing.
ByAinvest
Thursday, Jul 31, 2025 7:33 am ET1min read
• Fanapt net sales up 27% to $29.3 million in Q2 2025 • Bysanti NDA accepted for filing; PDUFA target action date Feb. 21, 2026 • Tradipitant NDA accepted for filing; PDUFA target action date Dec. 30, 2025 • Imsidolimab BLA submission expected in 2025 for generalized pustular psoriasis • Fanapt sales growth expected to continue in coming quarters • Broad direct to consumer brand awareness campaign underway
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) reported its second-quarter 2025 financial results on Thursday, July 31, 2025, highlighting significant growth in its core product, Fanapt®. The company's net product sales from Fanapt® increased by 27% to $29.3 million compared to the same period last year, driven by a robust direct-to-consumer brand awareness campaign [2].Key highlights from the quarterly report include:
1. Fanapt® Sales Growth: Fanapt® net product sales surged by 27% to $29.3 million, marking a significant increase from the $23.2 million reported in the second quarter of 2024 [2].
2. Regulatory Milestones: The company achieved substantial regulatory milestones with the acceptance for filing of Bysanti™ New Drug Application (NDA) for bipolar I disorder and schizophrenia, with a PDUFA target action date of February 21, 2026, and Tradipitant NDA for motion sickness, with a PDUFA target action date of December 30, 2025 [2].
3. Pipeline Advancements: Imsidolimab Biologics License Application (BLA) for generalized pustular psoriasis is expected to be submitted to the FDA in 2025, further strengthening Vanda's clinical pipeline [2].
4. Financial Guidance: Vanda reiterated its 2025 financial guidance, expecting total revenues to range between $210 million and $250 million, and end-year cash to be between $280 million and $320 million [2].
The company's management expressed optimism about the continued growth of Fanapt® sales, attributing it to the expansion of sales efforts and a broad direct-to-consumer brand awareness campaign [2]. This campaign has significantly elevated brand awareness for both Fanapt® and PONVORY®, contributing to the overall financial performance.
Reference List:
[1] https://www.defenseworld.net/2025/07/30/vanda-pharmaceuticals-vnda-projected-to-post-earnings-on-thursday.html
[2] https://www.marketscreener.com/news/vanda-pharmaceuticals-reports-second-quarter-2025-financial-results-ce7c5fdddb88f422
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet